2025 APRIL
Review
Pharmacol Rev. 2025;77:100023. Organic anion transporting polypeptides: Pharmacology, toxicology, structure, and transport mechanisms. Hagenbuch B, Stieger B, Locher KP. PubMed
Transporters of statins
Eur J Pharm Sci. 2025 Mar 17;209:107073. Comparative uptake of statins by hepatic organic anion transporting polypeptides. Kiander W, Sinokki A, Neuvonen M, Kidron H, Niemi M. PubMed
Eur J Pharm Sci. 2025;209:107070. Transport of statins by multidrug resistance-associated proteins 1 and 5.Tuomi SK, Deng F, Neuvonen M, Niemi M. PubMed
Transporters and liver disease
Clin Pharmacol Ther. 2025;In press. Impact of cancer cachexia progression on OATP1B1 transport activity: Quantitative analysis using coproporphyrin-I as an endogenous biomarker. Sumimoto T, Tanaka R, Suzuki Y, Negami J, Sueshige Y, Oda A, Shiraiwa K, Inagaki T, Nishikawa K, Tatsuta R, Otsu S, Ogata M, Ohno K, Itoh H. PubMed
Transplantation. 2025;In press. Acute response of hepatocyte MRP2 internalization as an indicator of ischemia-reperfusion injury in liver transplantation. Monti C, Hong SK, Lee A, Hong JC, Eriksen CM, Joshi A, Dash RK, Audi SH, Lee W, Kumar SN, Kim J. PubMed
Antimicrob Agents Chemother. 2025:e0189224. Impact of hepatic impairment and renal failure on the pharmacokinetics of linezolid and its metabolites: contribution of hepatic metabolism and renal excretion. Liu J, Pang Y, Li W, Sun J, He Y, Guo Y, Dong J. PubMed
BCRP biomarkers
Clin Pharmacol Ther. 2025;In press. Identification and clinical evaluation of potential biomarkers for Breast Cancer Resistance Protein (BCRP/ABCG2). Riselli AM, Yee SW, Yang J, Brett CM, Trumbach K, Zhou X, Liu R, Liang X, Lai Y, Huo R, Xue Y, Shen H, Zhang L, Yang X, Liu Q, Huang SM, Giacomini KM. PubMed
Hepatic drug clearance
Clin Pharmacol Ther. 2025;In press. Hepatic impairment and the differential effects on drug clearance mechanisms: Analysis of pharmacokinetic changes in disease state. Tang LWT, Varma MVS. PubMed
Transporter-mediated DDI
Clin Pharmacol Ther. 2025;117:1175-1178. Navigating the challenges of cyclosporine as an alternative to rifampicin as an OATP1B index inhibitor. Varma MVS, Vourvahis M. PubMed
Clin Pharmacol Ther. 2025;117:1393-1402. Intracellular penetration of atazanavir, ritonavir and dolutegravir with concomitant rifampicin: A dose escalation study. De Nicolò A, Palermiti A, Mugerwa H, Nakabuye S, Namusanje J, Kobusingye J, Odoch D, Lamorde M, Kengo A, Denti P, Gausi K, Maartens G, McIlleron H, Wiesner L, Khoo S, Waitt C, D'Avolio A. PubMed
Clin. Pharmacol Ther. 2025;In press. Quantitative contributions of hepatic and renal organic cation transporters to the clinical pharmacokinetic cimetidine-metformin interaction. Ailabouni AS, Singh DK, Thakur A, Boone EC, Gaedigk A, Paine MF, Prasad B. PubMed
Experimental models
Drug Metab Dispos. 2025;53:100055. Prediction of hepatic metabolic clearance in rats and dogs using long-term cocultured hepatocytes. Umehara K, Klammers F, Walter I, Naik T, Dudal V, Remus T, Ekiciler A, Anderka I, Pugliano A, Preiss L, Enlo-Scott Z, Njuguna N, Keemink J, Parrott N. PubMed
Drug Metab Pharmacokinet. 2025 Mar 13;62:101478. In vitro liver models for toxicological research. Fukunaga I, Takebe T. PubMed
Biofabrication. 2025;In press. A hollow fiber membrane-based liver organoid-on-a-chip model for examining drug metabolism and transport. Myszczyszyn A, Muench A, Lehmann V, Sinnige T, van Steenbeek FG, Bouwmeester M, Samsom RA, Keuper-Navis M, van der Made TK, Kogan D, Braem S, van der Laan LJW, Eslami Amirabadi H, van de Steeg E, Masereeuw R, Spee B. PubMed.
Commun Biol. 2025;8:531. A structural and mechanistic model for BSEP dysfunction in PFIC2 cholestatic disease. Gruget C, Reddy BG, Moore JM. PubMed
Comput Struct Biotechnol J. 2025;27:1215-1232. Membrane-dependent dynamics and dual translocation mechanisms of ABCB4: Insights from molecular dynamics simulations. Crespi V, Tóth Á, Janaszkiewicz A, Falguières T, Di Meo F PubMed